Presbyopia market LENZ Therapeutics is targeting presbyopia with VIZZ, a lead aceclidine eye drop, positioning for a global near-vision restoration market estimated for nearly two billion people. This creates a broad accessibility and clinician adoption opportunity across ophthalmology practices, optometry networks, and telemedicine channels.

US availability Commercial launch in the United States has occurred, with VIZZ now available in the market, suggesting immediate sales opportunities through hospital systems, ophthalmology clinics, and retail dispensing channels, supported by recent telehealth prescribing options to expand patient access.

Global partnerships LENZ has actively pursued exclusive licensing and commercialization agreements in Australia, New Zealand, Canada, and broader regions with partners like Arrotex Pharmaceuticals and Laboratoires Théa, indicating a scalable channel strategy that can be replicated for additional territories and payer partnerships.

Telehealth growth The introduction of a telehealth prescribing option signals a growth lever to accelerate patient access and adherence, offering a ready-made sales channel to clinicians and patients, and potential upsell opportunities for remote monitoring services and patient education programs.

Competitive landscape Positioned as a competitor to Vuity and Qlosi, LENZ can emphasize differentiators such as formulation, delivery, and regional partnerships to pursue co-promotion deals, contracting with payers, and strategic collaborations to expand market share against established players.